{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:40:12Z","timestamp":1767066012096,"version":"3.40.3"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmentalhealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Ment Health"],"abstract":"<jats:p>Ketamine is an NMDA receptor antagonist, long used for its anesthetic and pain reducing properties, but has more recently demonstrated efficacy for treating depression. Evidence is also emerging for other psychiatric indications including posttraumatic stress disorder, anxiety disorders, obsessive compulsive disorder, and to support psychotherapy. In this context, there is greater demand for its use in various forms including intravenous, intramuscular, subcutaneous, intranasal, oral, and sublingual administration. While intravenous administration typically requires administration and monitoring in a healthcare setting, the safety precautions for other forms of ketamine are unclear. Limited data in this regard may elicit controversy among prescribers, who wish to improve patient access, and among regulatory bodies, who may impose limitations based on IV ketamine data. This project aims to bridge the gap between current literature and the clinical experience and opinions of ketamine prescribers. This information was obtained in the form of a survey and answered: \u201cHow do prescribers of ketamine, with emphasis on psychiatric care providers, find its safety profile and in what ways have they prescribed ketamine?\u201d Information was gathered on prescriber profiles, indications for ketamine use, doses and routes of ketamine prescribed, side effects and adverse events, and prescribers\u2019 opinions regarding monitoring requirements. Results were obtained from 45 providers with more than 1000 patient encounters over two countries. Non-IV forms of ketamine were commonly used, and the survey reported a favorable safety profile for ketamine. Non-IV Ketamine was reported to be safely utilized in a clinic setting with minimal monitoring and safety equipment, or at times, for home use. While survey results carry limitations, it appears that safety is dependent on dose and route, and strict universal regulations for all formulations may unnecessarily limit patient access.<\/jats:p>","DOI":"10.1371\/journal.pmen.0000215","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:03:04Z","timestamp":1743634984000},"page":"e0000215","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmen.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ketamine for mental health - A naturalistic inventory of prescribing practices, safety, and adverse effects"],"prefix":"10.1371","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8597-3885","authenticated-orcid":true,"given":"Maegan","family":"Stuart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-6923","authenticated-orcid":true,"given":"Ian","family":"Stefanuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Comeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-1395","authenticated-orcid":true,"given":"Jennifer","family":"Swainson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"3","key":"pmen.0000215.ref001","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/0259-1162.143110","article-title":"Ketamine: current applications in anesthesia, pain, and critical care","volume":"8","author":"MS Kurdi","year":"2014","journal-title":"Anesth Essays Res"},{"issue":"5","key":"pmen.0000215.ref002","doi-asserted-by":"crossref","first-page":"appi.ajp.2020.2","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"R McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"10","key":"pmen.0000215.ref003","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-018-0941-8","article-title":"The walking wounded: emerging treatments for PTSD","volume":"20","author":"D Bestha","year":"2018","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"pmen.0000215.ref004","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review \u2013 Corrigendum","volume":"8","author":"Z Walsh","year":"2022","journal-title":"BJPsych Open"},{"issue":"11","key":"pmen.0000215.ref005","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"C Ly","year":"2018","journal-title":"Cell Rep"},{"issue":"15","key":"pmen.0000215.ref006","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"R Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"pmen.0000215.ref007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"J Dore","year":"2019","journal-title":"J Psychoactive Drugs"},{"key":"pmen.0000215.ref008","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance","volume":"11","author":"M Wolff","year":"2020","journal-title":"Front Psychiatry"},{"key":"pmen.0000215.ref009","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: R\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","author":"R Lam","year":"2024","journal-title":"Can J Psychiatry"},{"key":"pmen.0000215.ref010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"RS McIntyre","year":"2020","journal-title":"J Affect Disord"},{"issue":"2","key":"pmen.0000215.ref011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","article-title":"The Canadian network for mood and anxiety treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: Recommandations du groupe de travail du r\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) concernant l\u2019utilisation de la k\u00e9tamine rac\u00e9mique chez les adultes souffrant de trouble d\u00e9pressif majeur","volume":"66","author":"J Swainson","year":"2020","journal-title":"Can J Psychiatry"},{"issue":"1","key":"pmen.0000215.ref012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/acps.12572","article-title":"Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression","volume":"134","author":"CK Loo","year":"2016","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"pmen.0000215.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-022-04268-5","article-title":"Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study","volume":"22","author":"S Ahuja","year":"2022","journal-title":"BMC Psychiatry"},{"key":"pmen.0000215.ref014","doi-asserted-by":"crossref","first-page":"830301","DOI":"10.3389\/fpsyt.2022.830301","article-title":"Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial","volume":"13","author":"MA Cigognini","year":"2022","journal-title":"Front Psychiatry"},{"issue":"5","key":"pmen.0000215.ref015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/YIC.0000000000000409","article-title":"Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series","volume":"37","author":"JCW Tham","year":"2022","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"pmen.0000215.ref016","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"KAB Lapidus","year":"2014","journal-title":"Biol Psychiatry"},{"key":"pmen.0000215.ref017","article-title":"Intranasal ketamine for depression in adults: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"12","author":"D An","year":"2021","journal-title":"Front Psychol"},{"issue":"4","key":"pmen.0000215.ref018","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0269881118760660","article-title":"Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial","volume":"32","author":"V G\u00e1lvez","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"2","key":"pmen.0000215.ref019","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/0269881118822160","article-title":"A response to: Repeated intranasal ketamine for treatment resistant depression: the way to go? Results from a pilot randomised controlled trial","volume":"33","author":"V Lee","year":"2019","journal-title":"J Psychopharmacol"},{"key":"pmen.0000215.ref020","doi-asserted-by":"crossref","first-page":"1016439","DOI":"10.3389\/fpsyt.2022.1016439","article-title":"A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: a preliminary evaluation of real world addictive potential","volume":"13","author":"B Chubbs","year":"2022","journal-title":"Front Psychiatry"},{"key":"pmen.0000215.ref021","first-page":"1","article-title":"Oral ketamine for depression: an updated systematic review","author":"S Meshkat","year":"2023","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"pmen.0000215.ref022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1192\/bjp.2018.196","article-title":"Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"214","author":"Y Domany","year":"2019","journal-title":"Br J Psychiatry"},{"issue":"6","key":"pmen.0000215.ref023","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/JCP.0000000000001289","article-title":"Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study","volume":"40","author":"D Kheirabadi","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"pmen.0000215.ref024","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","article-title":"Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial","volume":"235","author":"S Arabzadeh","year":"2018","journal-title":"J Affect Disord"},{"key":"pmen.0000215.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2016.05.076","article-title":"Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial","volume":"204","author":"M Jafarinia","year":"2016","journal-title":"J Affect Disord"},{"key":"pmen.0000215.ref026","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"TD Hull","year":"2022","journal-title":"J Affect Disord"},{"key":"pmen.0000215.ref027","first-page":"2667","article-title":"Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review","volume":"11","author":"L Nguyen","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"pmen.0000215.ref028","volume-title":"Spravato (esketamine hydrochloride): 28\u2009mg, solution for intranasal use [product monograph]","year":"2020"},{"key":"pmen.0000215.ref029","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1283733","article-title":"Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada","volume":"14","author":"C Chrenek","year":"2024","journal-title":"Front Psychiatry"},{"key":"pmen.0000215.ref030","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: a scoping review of preclinical and clinical studies","volume":"151","author":"T Le","year":"2022","journal-title":"J Psychiatric Res"},{"key":"pmen.0000215.ref031","article-title":"Non-parenteral ketamine for depression: a practical discussion on addiction potential and recommendations for judicious prescribing","author":"J Swainson","year":"2022","journal-title":"CNS Drugs"},{"key":"pmen.0000215.ref032","article-title":"Intravenous ketamine for depression: a clinical discussion reconsidering best practices in acute hypertension management","volume":"13","author":"R Yip","year":"2022","journal-title":"Front Psychiatry"},{"issue":"3","key":"pmen.0000215.ref033","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"P Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"3","key":"pmen.0000215.ref034","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00266-018-1103-4","article-title":"Prevention of emergence agitation with ketamine in rhinoplasty","volume":"42","author":"C Demir","year":"2018","journal-title":"Aesthetic Plast Surg"}],"container-title":["PLOS Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmen.0000215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:04:32Z","timestamp":1743635072000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmen.0000215"}},"subtitle":[],"editor":[{"given":"Hongru","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmen.0000215","relation":{},"ISSN":["2837-8156"],"issn-type":[{"value":"2837-8156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]}}}